Trial
NCT05960773
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
Phase IISUSPENDEDOTHER/UNKNOWNConfidence: LOW
Sponsor
National Cancer Institute (NCI)
Collaborators
—
Condition
Mesothelioma
Intervention
Decitabine/cedazuridine
Why stopped
On hold pending updates to the drug/manufacturer information.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-05